See related article, pp. 858-867Myocardial nuclear perfusion imaging represents the most extensively used non-invasive diagnostic and prognostic tool for coronary artery disease. As reviewed in an excellent editorial by Dahlberg, 1 the suboptimal physical characteristics of the historical agent Tl-201 have prompted the development of Tc-99 m-labeled myocardial perfusion imaging agents with more favorable emission energy and dosimetry. For a number of reasons that were addressed in the abovementioned editorial, and despite excellent myocardial extraction and encouraging clinical results, the neutral and lipophilic tracers TcN-NOET and Tc-TEBOROXIME have not reached routine clinical use. 1 On the other hand, the cationic and lipophilic tracer Tc-MIBI has been extensively studied experimentally 2-10 and has reached wide clinical acceptance for a number of years. However, in addition to suboptimal myocardial extraction in comparison to that of Tl-201 due to the roll-off phenomenon leading to underestimation of myocardial perfusion at high flow rates, 7 Tc-MIBI also presents a modest heartto-liver activity ratio which is comparable or lower than that of Tl-201 and which might be responsible for misinterpretation of myocardial perfusion in the inferior or inferoapical left ventricular wall. 11,12 In the clinical setting however, despite these different biological, physical, and imaging characteristics, both Tl-201 and Tc-MIBI have comparable diagnostic accuracies for detecting coronary artery disease, as confirmed in the large randomized ROBUST study. 12 Similarly, the prognostic power of nuclear perfusion imaging-i.e., its ability for predicting future coronary events-has been demonstrated in a large number of high-quality studies and in thousands of patients, whatever the tracer used. 13 Tc-TETROFOSMIN is another cationic and lipophilic tracer of myocardial perfusion that was approved for clinical use 6 years after Tc-MIBI. The cellular uptake mechanisms of both tracers consist in mitochondrial accumulation due to the negative mitochondrial membrane potential and the positive charge associated with the lipophilicity of the tracers. Although Tc-TE-TROFOSMIN presents a flow-extraction curve similar to that of Tc-MIBI, 14 the heart-to-liver ratio of the tracer turned out to be significantly higher than that of Tc-MIBI in the clinical setting. 15 The more favorable liver kinetics of Tc-TETROFOSMIN resulted in a lower number of poor quality scans than observed with Tc-MIBI in daily practice, 16 a result which however did not lead to differences in sensitivity, specificity, and diagnostic accuracy between the two tracers. 17 As described below, a number of experimental studies including the paper by Liu et al 18 in this issue of the Journal have addressed the issue of developing new myocardial perfusion imaging agents with improved myocardial and/or liver kinetics in comparison with those of Tc-MIBI. Although these studies often yielded encouraging experimental results, the current literature clearly lacks clinical data c...